Serum Institute of India to resume Oxford-AstraZeneca COVID-19 vaccine trials; gets DCGI nod
The Drugs Controller General of India (DCGI) has allowed the Serum Institute of India (SII) to resume its phase two and three clinical trials for the Oxford-AstraZeneca COVID-19 vaccine.
No comments:
Post a Comment